Tacrolimus-induced pulmonary injury in rheumatoid arthritis patients

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 4, 2011, Pages 401-406

  Koike, Ryuji ^a   Tanaka, Michi ^a   Komano, Yukiko ^a   Sakai, Fumikazu ^b   Sugiyama, Haruhito ^c   Nanki, Toshihiro ^a   Ide, Hiroshi ^d   Jodo, Satoshi ^e   Katayama, Kou ^f   Matsushima, Hidekazu ^g   Miwa, Yusuke ^h   Morita, Koichi ⁱ   Nakashima, Hiroshi ^j   Nakamura, Hiroyuki ^k   Natsumeda, Masamitsu ^l   Sato, Yoshiko ^m   Semba, Seitaro ^k   Tateishi, Mutsuto ⁿ   Miyasaka, Nobuyuki ^a   Harigai, Masayoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d Asahikawa Kosei General Hospital   (Japan)

^e Tomakomai City General Hospital   (Japan)

^f Katayama Orthopedic Rheumatology Clinic   (Japan)

^g SAITAMA RED CROSS HOSPITAL   (Japan)

^h SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ Morita Medical Clinic   (Japan)

^j Nakashimahiroshi Clinic   (Japan)

^k TOKYO MEDICAL UNIVERSITY   (Japan)

^l Kurashiki Kousai Hospital   (Japan)

^m MIE UNIVERSITY   (Japan)

ⁿ Tokyo Metropolitan Ohtsuka Hospital   (Japan)

more..

Author keywords

Drug toxicity arthritis; Lung disease; Lung injury; Tacrolimus

Indexed keywords

BUCILLAMINE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; TOSUFLOXACIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; HYPERSENSITIVITY; INTERSTITIAL PNEUMONIA; LOEFFLER PNEUMONIA; LUNG INJURY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MULTIPLE CYCLE TREATMENT; POLYARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; MALE; MIDDLE AGED; RADIOGRAPHY, THORACIC; TACROLIMUS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79956067778     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.01.016     Document Type: Article

References (27)

1. Wallemacq P.E., Reding R. FK506 (Tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin Chem 1993, 39:2219-2228.
2. Scott L.J., McKeage K., Keam S.J., Plosker S.J., Greg L. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003, 63:1247-1297.
3. Kondo H., Abe T., Hashimoto H., Uchida S., Irimajiri S., Hara M., et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004, 31:243-251.
4. Kawai S., Hashimoto H., Kondo H., Murayama T., Kiuchi T., Abe T. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol 2006, 33:2153-2161.
5. Kawai S., Tanaka K., Ohno I., Utsunomiya K., Seino Y. Safety of long-term tacrolimus therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients. Mod Rheumatol 2008, 18:345-353.
6. Miyasaka N., Kawai S., Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol 2009, 19:606-615.
7. Takada K., Nagasaka K., Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005, 38:383-392.
8. Takada K., Kishi J., Miyasaka N. Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: a retrospective study. Mod Rheumatol 2007, 17:123-130.
9. Report of interstitial pneumonia and Pneumocystis jirovecii pneumonia in rheumatoid arthritis under tacrolimus therapy 2008, Subcomittee for postmarketing surveillance of tacrolimus, Japan College of Rheumatology, Astellas Pharma Inc., Tokyo, [in Japanese].
10. Miwa Y., Isozaki T., Wakabayashi K., Odai T., Matsunawa M., Yajima N., et al. Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis. Mod Rheumatol 2008, 18:208-211.
11. Arnett F.C., Edworthy S.M., Bloch D.A., Mcshane D.J., Fries J.F., Cooper N.S., et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
12. Camus P., Fanton A., Bonniaud P., Camus C. Interstitial lung disease induced by drugs and radiation. Respiration 2004, 71:301-326.
13. Kohno N., Kyoizumi S., Awaya Y., Furuhara H., Yamakido N., Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989, 96:68-73.
14. Nakajima H., Harigai M., Hara M., Hakoda M., Tokuda H., Sakai F., et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 2000, 27(5):1164-1170.
15. Lock B.J., Eggert M., Cooper J.A.D. Infiltrative lung disease due to noncytotoxic agents. Clin Chest Med 2004, 25:47-52.
16. Saravanan V., Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology 2006, 45:787-789.
17. Anaya J.-M., Diethelm L., Ortiz L.A., Gutierrez M., Citera G., Welsh R.A., et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 1995, 24:242-254.
18. Cohen S., Cannon G.W., Schiff M., Weaver A., Fox R., Olsen N., et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001, 44:1984-1992.
19. Kalden J.R., Schattenkirchner M., Sorensen H., Emery P., Deighton C., Rozman B., et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis. A five-year followup study. Arthritis Rheum 2003, 48:1513-1520.
20. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004, 363:461.
21. Ochi S., Harigai M., Mizoguchi F., Iwai H., Hagiyama H., Oka T., et al. Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage. Mod Rheumatol 2006, 16:316-320.
22. Ogiwara Y., Mochizuki H., Morioka T., Sugihara T., Makino F., Takahashi H. A case with life-threatening interstitial pneumonia associated with bucillamine treatment. Mod Rheumatol 2008, 18:522-525.
23. Przepiorka D., Abu-Elmagd K., Huaringa A., Luna M., van Besian K., Starzl T.E., et al. Bronciolitis obliterans organizing pneumonia in a BMT patient receiving FK506. Bone Marrow Transplant 1993, 11:502.
24. Jinta M., Ohashi K., Ohta T., Ieki R., Abe K., Kamata N., et al. Clinical features of allogeneic hematopoietic stem cell transplantation-associated organizing pneumonia. Bone Marrow Transplant 2007, 40:465-472.
25. Gad S.C. Postmarketing safety evaluation: monitoring, assessing, and reporting of adverse drug responses. Drug safety evaluation 2009, 935-971. John Wiley & Sons, Inc., Hoboken, NJ. 2nd ed. S.C. Gad (Ed.).
26. Suissa S., Hudson M., Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006, 54:1435-1439.
27. Sakai F., Noma S., Kurihara Y., Yamada H., Azuma A., Kudoh S., et al. Leflunomide-related lung injury in patients with rheumatoid arthritis. Mod Rheumatol 2005, 15:173-179.